32 related articles for article (PubMed ID: 25907246)
1. Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?
Zheng L
Immunotherapy; 2014; 6(10):1017-20. PubMed ID: 25428641
[No Abstract] [Full Text] [Related]
2. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer.
Bass KK; Mastrangelo MJ
Cancer Immunol Immunother; 1998 Sep; 47(1):1-12. PubMed ID: 9755873
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA CRNDE promotes malignant progression of hepatocellular carcinoma through the miR-33a-5p/CDK6 axis.
Lin C; Xiang Y; Sheng J; Liu S; Cui M; Zhang X
J Physiol Biochem; 2020 Aug; 76(3):469-481. PubMed ID: 32621257
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with low-frequency ultrasound irradiation and radiofrequency ablation as a synergistic treatment for pancreatic cancer.
Wang H; Ding W; Shi H; Bao H; Lu Y; Jiang TA
Bioengineered; 2021 Dec; 12(2):9832-9846. PubMed ID: 34696663
[TBL] [Abstract][Full Text] [Related]
5. Mycobacteria-Based Vaccines as Immunotherapy for Non-urological Cancers.
Noguera-Ortega E; Guallar-Garrido S; Julián E
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32635668
[TBL] [Abstract][Full Text] [Related]
6. Immunologic approaches to the management of pancreatic cancer.
Laheru D; Biedrzycki B; Jaffee EM
Cancer J; 2001; 7(4):324-37. PubMed ID: 11561608
[TBL] [Abstract][Full Text] [Related]
7. Potential targets for pancreatic cancer immunotherapeutics.
Dodson LF; Hawkins WG; Goedegebuure P
Immunotherapy; 2011 Apr; 3(4):517-37. PubMed ID: 21463193
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic potency of HSP65-GTL in GL261 glioma-bearing mice.
Yan Y; Fang M; Xuan W; Wu X; Meng X; Wang L; Yu Y
J Immunother; 2015; 38(9):341-9. PubMed ID: 26448578
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with TCL plus MHSP65 induces anti-lung cancer immunity in mice.
Dong B; Sun L; Wu X; Zhang P; Wang L; Wei H; Zhou L; Hu X; Yu Y; Hua S; Wang L
Cancer Immunol Immunother; 2010 Jun; 59(6):899-908. PubMed ID: 20087582
[TBL] [Abstract][Full Text] [Related]
10. [Effect of MHSP65-TCL anti-melanoma vaccine on the activity of immunocytes].
Dong B; Dai G; Qi Z; Yang G; Lu J; Zhang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Nov; 33(11):1673-7. PubMed ID: 24273276
[TBL] [Abstract][Full Text] [Related]
11. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with FasL-/TCL plus MHSP65 induces improved anti-lung cancer immunity in mice.
Dong B; Dai G; Ding Y; Wang B; Zhang S
Int Immunopharmacol; 2018 Feb; 55():306-311. PubMed ID: 29310106
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of mHSP65-TTL enhanced by administration of low dose cyclophosphamide in pancreatic cancer-bearing mice.
Xuan W; Yan Y; Wan M; Wu X; Ji D; Wang L; Lin C; Chen Y; Yu Y; Zhang X
Int Immunopharmacol; 2015 Jul; 27(1):95-103. PubMed ID: 25907246
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
